8 citations
,
October 2002 in “Journal Of Clinical Periodontology” Levamisole and finasteride can reduce DHT production, potentially preventing phenytoin-induced gum overgrowth.
January 2026 in “Elsevier eBooks”
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
January 2009 in “Acta urologica Belgica” Finasteride effectively treats BPH by reducing prostate size and improving symptoms.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
September 2015 in “Photodiagnosis and Photodynamic Therapy” 31 citations
,
September 2019 in “Acta Pharmacologica Sinica”
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
30 citations
,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
January 2012 in “Земский врач” Finasteride helps improve treatment for benign prostatic hyperplasia.
July 2006 in “Inpharma Weekly”
37 citations
,
May 2007 in “International Journal of Pharmaceutics” PPCM microspheres allow controlled finasteride release over 24 hours.
January 2012 in “Курский научно-практический вестник "Человек и его здоровье"” 5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
April 2010 in “Nature Reviews Urology”
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
The document's conclusion cannot be provided because the document is not available or cannot be read.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
January 2011 in “Reactions Weekly”
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
October 2025 in “Proceedings of the National Academy of Sciences” Phospholipids help plant proteins move by regulating receptor interactions.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
August 2024 in “Biomolecules & Therapeutics” A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.